FDA Approvals: Is it really as bad as they say?
This week we're greeted with the following headlines: The FDA Approvals of 2013: A Watershed? US new drug approvals slip in 2013 vs prior year An ominous trend…
Menu
Making progress against Hepatitis C
Those of us of a certain vintage will remember the days when interferon was the only option for hepatitis C patients. Then, the pegylated versions were launched and…
BIO Europe 2013 – Tying It All Together
We've returned from another successful BIO Europe conference, this time in Vienna. We regret not having much time to walk around in Vienna. However, this did not take away…
BIO Europe Preparation Video
Lacerta Bio is pleased to announce our participation in the 19th Annual BIO-Europe Conference in Vienna, Austria. As with last year's conference in Hamburg, this year's…
Ben Venue to close: Wither Parenterals?
Ed Silverman at Pharmalot reports today that BI is closing Ben Venue once and for all: More than two years after Ben Venue Laboratories began encountering serious quality…
Webinar Follow Up Questions
We recently presented a 30-minute live webinar on ways to improve your business development process. The webinar recording is available here. We also have an annotated transcript available, which you…
Indian pharma draws more FDA scrutiny
We've posted about the Indian pharmaceutical market before, but this report is downright shocking: U.S. inspectors visiting a factory in India owned by drugmaker Wockhardt Ltd in March…
Biogeneric infliximab now available in Europe
Today we learn that a biogeneric form of Remicade, the first biogeneric monoclonal antibody, will shortly be available in Europe: Tuesday's final green light for Inflectra - which…
September Tips
September is a strange month, isn't it? It's the unofficial end of summer, so we're all getting back into the swing with everyone back in the office. Yet…
If It’s Difficult, Do It
Today we learn that Endo is acquiring Boca Pharmacal for $225 million: Boca Pharmacal is a specialty generics company that focuses on niche areas, commercializing and developing products…
- Go to the previous page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- …
- 33
- Go to the next page